Roche's Tecentriq-Avastin lung cancer combo gets a lift from England's cost watchdogs

tecentriq
Roche's Tecentriq-Avastin-chemo combo won FDA approval in December. (Roche)

Roche has some hard-earned knowledge about working with England’s cost watchdogs, especially where its cancer drugs are concerned. And it put that know-how to use to score backing for Tecentriq in lung cancer.

The National Institute of Health and Care Excellence (NICE) decided to back the immuno-oncology drug, in combination with Roche’s Avastin and chemo, in previously untreated non-small cell lung cancer (NSCLC), the Swiss drugmaker said Thursday.

The nod covers non-squamous NSCLC patients whose tumors express low levels of PD-L1 or don’t express the biomarker at all. And it applies to those with EGFR- or ALK-positive tumors who've have failed on targeted therapy.

On-Demand Webinar

Leveraging A Medical Record-Enriched Patient Dataset for COVID-19 Research

You are invited to join a webinar that will explore the ways researchers can leverage this enriched dataset for important COVID-19 research. Sign up today for this informative webinar to learn how you can leverage one of the only medical record reviews solely using real-world data from hospitalized COVID-19 patients.

RELATED: Roche’s Tecentriq wins key lung cancer approval. Its prize? A showdown with formidable Merck

But NICE had some conditions when it agreed to foot the bill for Tecentriq. For one, patients must stop the combo after two years of uninterrupted treatment—or earlier, if their disease progresses. And they’ll only get the cocktail if Roche sticks to a confidential price break it served up in negotiations with the gatekeeper.

“There is uncertainty about the company’s long-term survival estimates, especially for people with EGFR- or ALK-positive NSCLC. But including the most plausible assumptions and the commercial arrangements, the cost-effectiveness estimates are within what NICE normally considers acceptable for an end-of-life treatment,” NICE said in final guidance.

Even with the restrictions, the NICE decision opens up treatment for 4,800 patients in England, according to Roche’s estimates. And that’s good news for Roche, which is jockeying for position in the first-line lung cancer field against Merck & Co., whose Keytruda had broader approval in the setting—along with a head start—when Tecentriq launched.

RELATED: In a win for Roche, cost gatekeepers change tune to back Tecentriq in lung cancer

Meanwhile, Roche, which has a contentious history with NICE, can add to its list of Tecentriq indications the agency endorses. Last April, NICE changed its mind and issued a positive decision on Tecentriq as a treatment for previously treated lung cancer.

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.